



Compassion Service Education

GKCT

8th International ANNUAL REVIEW

On Gastrointestinal Cancer

 Taj Santacruz, Mumbai

 12th & 13th July 2025



Dr. Anil Heroor

Consultant Surgical Oncologist,
Anil Cancer Clinic, Thane,
Mulund, Dombivli



Dr. Tejinder Singh

Consultant Medical Oncologist,
Apollo Cancer Center,
Apollo Hospital, Navi Mumbai



Dr. Adwaita Gore

Consultant Medical Oncologist,
Saifee Hospital, Nanavati Max,
Zen Hospital, Mumbai

Scan & Register



FOR ANY QUARIES


 99884 63222

 annualreviewgicancers@gmail.com

In association with



 www.annualreviewgicancers.com



Dear Colleagues,

In the backdrop of an ever-increasing burden of gastrointestinal (GI) cancers in India, the need for unified, informed, and impactful action is more urgent than ever. As documented in recent national and global cancer registries, GI cancers—ranging from the esophagus and stomach to the gallbladder, colon, and pancreas—continue to challenge clinicians, researchers, and healthcare systems alike.

At Gopalkrishna Charitable Trust (GKCT), we remain committed to addressing this public health crisis through sustained awareness, education, and evidence-based practice. Our efforts are grounded in the belief that integrating preventive oncology into primary healthcare, supported by robust community engagement and clinical excellence, is essential for transforming outcomes.

We are therefore pleased to announce the 8th International Annual Review on Gastrointestinal Cancer Update, to be held on July 12th–13th, 2025, at Hotel Taj Santacruz, Mumbai. This premier academic gathering will once again bring together thought leaders, oncologists, GI specialists, and researchers to distill key learnings from major global conferences and recent landmark publications.

This year's review promises to deliver a concise, high-impact synthesis of rapidly evolving trends in GI oncology, enabling us to translate the latest scientific data into meaningful clinical decisions. We invite your active participation in this shared mission to improve GI cancer care across India and beyond.

Together, let us shape the future of gastrointestinal oncology.

Warm regards



Dr. Anil Heroor

Consultant Surgical Oncologist,
Anil Cancer Clinic, Thane, Mulund, Dombivali



Dr. Tejinder Singh

Consultant Medical Oncologist,
Apollo Cancer Center, Apollo Hospital, Navi Mumbai




Dr. Adwaita Gore

Consultant Medical Oncologist,
Saifee Hospital, Nanavati Max, Zen Hospital, Mumbai

In association with

Scan & Register





Conference Highlights

The 8th GI Review 2025 continues its legacy as a premier academic gathering that brings together multi-disciplinary insights into gastrointestinal cancers, covering the full spectrum from the esophagus and stomach to the pancreas, hepatobiliary system, small bowel, colon, rectum, and anal canal.

With the growing complexity of cancer care and the deluge of clinical, translational, and basic research presented annually, it is increasingly challenging—even for subspecialists—to stay abreast of the most practice-changing evidence. This focused two-day meeting aims to distill and critically appraise the most impactful original scientific data presented at the major global conferences over the past year, including:

- ASCO
- ESMO
- ASCOGI
- WORLDGI
- ESMOGI
- JCO
- NEJM
- BJC
- EJSO
- Lancet Oncology
- Journal of GI Oncology
- EJC

Each session is structured to provide a concise update on advances in surgical, radiation, and medical oncology, as well as on pathology, biomarkers, imaging, and evolving multimodal strategies. We will comprehensively review the latest developments in:

- ✓ Surgery and minimal access approaches
- ✓ Systemic therapies including chemotherapy and immunotherapy
- ✓ Targeted and molecular therapies
- ✓ Novel biomarkers and imaging modalities
- ✓ Treatment of early-stage and advanced/metastatic GI malignancies


Every session will conclude with an expert-led panel discussion translating presented data into real-world clinical decisions, making the discussions highly relevant and interactive

Who Should Attend

This program is curated for medical oncologists, surgical oncologists, gastroenterologists, radiation oncologists, pathologists, hepatologists, GI surgeons, clinical researchers, and other healthcare professionals involved in the diagnosis and treatment of GI cancers. Attendees will benefit from expert commentary, interactive case-based discussions, and the latest perspectives on standard and emerging care paradigms.

The 8th GI Review is more than just an update—it is a platform to shape evidence-based GI cancer care for the coming year.





AGENDA

12th July 2025

08:20 - 08:55 ➤ **Registration & Breakfast**

08:55 - 09:00 ➤ **Welcome address**

SESSION 1 ESOPHAGEAL CANCER


CHAIRPERSON : Dr.Sanjay Dudhat | Dr. Bharat Parikh | Dr. Amol Bhanushali

- 08:50 - 08:55 ➤ **Abstract 1** - SCIENCE Trial (LBA329)
This phase 3 study evaluates chemotherapy plus sintilimab and chemoradiotherapy plus sintilimab vs chemoradiotherapy alone as neoadjuvant treatments for patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC).
SPEAKER : Dr. Roshini Pandey
REVIEWER : Dr. B. K. Smruti
- 08:55 - 09:00 ➤ **Abstract 2** - Impact of time-of-day on nivolumab monotherapy infusion in patients with metastatic gastric cancer.
SPEAKER : Dr. Shreya Gattani
REVIEWER : Dr. B. K. Smruti
- 09:00 - 09:05 ➤ **Abstract 3** - Tevimbra Enhances Preoperative Outcomes in Esophageal Cancer
SPEAKER : Dr. Niyati Shah
REVIEWER : Dr. B. K. Smruti
- 09:05 - 09:10 ➤ **Abstract 4** - CheckMate-9KZ
A Phase 3 Trial of Neoadjuvant Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Resectable Esophageal and Gastroesophageal Junction Cancers
SPEAKER : Dr. Mayur Mane
REVIEWER : Dr. Avinash Deo
- 09:10 - 09:15 ➤ **Abstract 5** - Teslelizumab Plus Chemoradiotherapy Versus Chemoradiotherapy Alone in Locally Advanced Esophageal Squamous Cell Carcinoma: Interim Analysis of the Phase 3 TORCH-E Trial
SPEAKER : Dr. Jinesh Singhavi
REVIEWER : Dr. Avinash Deo
- 09:15 - 09:25 ➤ TORIPALIMAB plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma: A multi-center phase III trial (JUPITER 06)
SPEAKER : Dr. Tejinder Singh (Sponsored by Dr Ready's)
- 09:25 - 09:30 ➤ **Surgical Abstract 6** - Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial
SPEAKER : Dr. Mrunal Parab
REVIEWER : Dr. Nikhil Dharmadhikari
- 09:30 - 09:35 **Surgical Abstract 7** - Comparison of indocyanine green-near-infrared uorescence guided and traditional mediastinal lymphadenectomy during radical esophagectomy: A randomized controlled trial
SPEAKER : Dr. Deep Mashru

In association with

Scan & Register





AGENDA

12th July 2025

- 09:35 - 09:40 ➤ **Surgical Abstract 8** - Minimally Invasive transCervical oEsophagectomy (MICE) for oesophageal cancer: prospective cohort study (IDEAL stage 2A)
SPEAKER : Dr. Harshit Shah
REVIEWER : Dr. Nikhil Dharmadhikari
- 09:40 - 10:00 ➤ **Emerging immunotherapies in Esophageal Cancer** - Glenmark Sponsored Session
SPEAKER : Dr. Tejinder Singh
- 10:00 - 10:20 ➤ **Abstract Based Panel Discussion** : Esophagus Cancer - Glenmark Sponsored Session
MODERATOR : Dr. Chandrashekhar Pethe
PANELISTS : Dr. Niyati Shah | Dr. Jinesh Sanghavi | Dr. Mubarakunnisa Tonse
Dr. Shreya Gattani | Dr. Mayur Mane | Dr. Roshni Pande
Dr. B. K. Smruti | Dr. Avinash Deo | Dr. Mrunal Parab
Dr. Harshit Shah | Dr. Deep Mashru | Dr. Priya Eshpuniyani
Dr. Nikhil Dharmadhikari

SESSION 2 GASTRIC CANCERS


Chairperson : Dr. Joseph Sequeira | Dr. Indoo Ammbulkar

- 10:20 - 10:25 ➤ **Abstract 9** - EORTC-1203 GITC INNOVATION Trial (LBA331)
This phase 2 trial evaluates the integration of trastuzumab with or without pertuzumab into perioperative chemotherapy for patients with HER2-positive stomach cancer. Overall survival results may cement the role of HER2-targeted therapies.
SPEAKER : Dr. Goli Vasu
REVIEWER : Dr. Suman Mittal
- 10:25 - 10:30 ➤ **Abstract 10** - ASPEN-06 Phase 2/3 Study (Abstract 332): This study examines evorpcept, a CD47 myeloid checkpoint inhibitor, in HER2-overexpressing gastric or gastroesophageal junction cancer, showing clinically meaningful improvements in overall response rate and duration of response.
SPEAKER : Dr. Amol Kotalwar
REVIEWER: Dr Suman Mittal
- 10:30 - 10:35 ➤ **Abstract 11** - CheckMate 649 (Abstract 398)
Five-year follow-up data confirms the long-term benefits of nivolumab plus chemotherapy as first-line treatment for advanced gastric, GEJ, and esophageal adenocarcinomas.
SPEAKER : Dr. Varun Nagori
REVIEWER: Dr Suman Mittal
- 10:35 - 10:40 ➤ **Abstract 12** - MATTERHORN Trial
Durvalumab plus FLOT chemotherapy meets primary endpoint of event-free survival in resectable gastric/gastroesophageal junction cancer.
SPEAKER : Dr. Gayatri Raheja
REVIEWER: Dr. Vijay Sharnangat
- 10:40 - 10:45 ➤ **Abstract 13** - CheckMate 577 Trial
Adjuvant nivolumab shows potential in resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy.
SPEAKER : Dr. Sanjay Agrawal
REVIEWER: Dr. Vijay Sharnangat

In association with

Scan & Register





AGENDA

12th July 2025

- 10:45 - 10:50 ➤ **Abstract 14** - Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJAJ): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study
SPEAKER : Dr. Dinky Gajiwala
REVIEWER: Dr. Vijay Sharnangat
- 10:50 - 10:55 ➤ **Surgical Abstract 15** - Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial
SPEAKER : Dr. Ambarish Chatterjee
Reviewer : Dr. Rajesh Shinde
- 10:55 - 11:00 ➤ **Surgical Abstract 16** - Total versus proximal gastrectomy for proximal gastric cancer after neoadjuvant chemotherapy: a multicenter retrospective propensity score-matched cohort study
SPEAKER : Dr. Pratik Doshi
REVIEWER: Dr. Rajesh Shinde
- 11:00 - 11:05 ➤ **Surgical Abstract 17** - Beyondscalpels: A meta-analysis of robotic and laparoscopic gastrectomy in long-term oncological outcomes in gastric cancer
SPEAKER : Dr. Tejas Vispute
REVIEWER: Dr. Rajesh Shinde
- 11:05 - 11:25 ➤ **Abstract Based Panel Discussion** : Gastric cancers
MODERATOR : Dr. Shailesh Bondarde
PANELISTS : Dr. Goli Vasu | Dr. Amol Kotalwar | Dr. Varun Nagori
Dr. Gayatri Raheja | Dr. Sanjay Agrawal | Dr. Dinky Gajiwala
Dr. Pratik Doshi | Dr. Vijay Sharnangat | Dr. Rajesh Shinde
Dr. Ambarish Chatterjee | Dr. Tejas Vispute

SESSION 3 HEPATO PANCREATIC BILIARY CANCER

Chairperson: Dr. Satish Kamath | Dr. Ram Krishna Prabhu | Dr. Anjana Sainani


- 11:25 - 11:30 ➤ **Abstract 18** - SEQUOIA Trial: Zanidatamab + Chemotherapy in 1L HER2+ BTC
SPEAKER : Dr. Suman Mittal
REVIEWER: Dr. Adwaita Gore
- 11:30 - 11:35 ➤ **Abstract 19** - EMERALD-3: Durvalumab + Chemotherapy + Bevacizumab in First-Line Advanced BTC
SPEAKER : Dr. Darshana Rane
REVIEWER: Dr. Adwaita Gore
- 11:35 - 11:40 ➤ **Abstract 20** - FGFR2 Inhibitor Resistance Mechanisms and Combination Approaches in Cholangiocarcinoma
SPEAKER : Dr. Dewesh Kishan
REVIEWER: Dr. Adwaita Gore
- 11:40 - 11:45 ➤ **Abstract 21** - CheckMate-9DW Final OS Analysis
Nivolumab + Ipilimumab vs Sorafenib in Advanced HCC
SPEAKER : Dr. Kunal Jobanputra
REVIEWER: Dr. Anjana Sainani

In association with



Scan & Register





AGENDA

12th July 2025

- 11:45 - 11:50 ➤ **Abstract 22** - TACT-HCC
TACE + Atezolizumab/Bevacizumab vs TACE Alone in Intermediate-Stage HCC
SPEAKER: Dr. Jay Mehta
REVIEWER: Dr. Anjana Sainani
- 11:50 - 11:55 ➤ **Abstract 23** - HCC - ablation, tace Radiologist
SPEAKER : Dr. Amit Sahu
REVIEWER: Dr. Anjana Sainani
- 11:55 - 12:00 ➤ **Surgical Abstract 24** -Robotic versus open partial pancreatoduodenectomy (EUROPA): a randomised controlled stage 2b trial
SPEAKER: Dr. Vikas Gupta
REVIEWER: Dr. Vikram Chaudhari | Dr. Prashant Kadam
- 12:00 - 12:05 ➤ **"Surgical Abstract 25** -Abstract Presentation - RESCUE-HCC: Randomized Trial of Laparoscopic vs Open Hepatectomy for Resectable HCC in Cirrhotics
SPEAKER : Dr. Makarand Bhole
REVIEWER: Dr. Vikram Chaudhari | Dr. Prashant Kadam
- 12:05 - 12:10 ➤ **Surgical Abstract 26** - Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trial
SPEAKER: Dr. Aditya Punamiya
REVIEWER: Dr. Vikram Chaudhari | Dr. Prashant Kadam
- 12:10 - 12:30 ➤ **Abstract Based Panel Discussion** : Hepato Pancreatic Biliary Cancer
MODERATOR : Dr. Suhas Agre
PANELISTS :

Dr. Suman Mittal	Dr. Darshana Rane	Dr. Dewesh Kishan
Dr. Kunal Jobanputra	Dr. Jay Mehta	Dr. Amit Sahu
Dr. Vikas Gupta	Dr. Prashant Kadam	Dr. Ketul Shah
Dr. Sharaddha Patkar	Dr. Nilesh Lokeshwar	Dr. Vikram Chaudhari
Dr. Makarand Bhole		
- 12:30 - 12:50 ➤ The Promise of Precision in IDH1 mutated Cholangiocarcinoma with Ivosidenib
SPEAKER : Sponsored by Servier
- 12:50 - 13:05 ➤ Real World Evidence from India_Durvalumab+GemCis is the new SOC in Advanced Biliary Tract Cancers
SPEAKER : Sponsored by Astrazeneca
- 13:05 to 13:25 ➤ AI in healthcare Workshop for clinicians - Exclusive session by
SPEAKER : Dr. Avinash Deo (Working LUNCH)

SESSION 4 HEPATO PANCREATIC BILIARY CANCER

Chairperson : Dr. B. A. Krishna | Dr. Sharvari Poojari


- 13:25 - 13:30 ➤ **Abstract 27**
177Lu-DOTATATE vs Sunitinib: Comparison of treatments for advanced grade 2 pancreatic neuroendocrine tumors using matching-adjusted indirect comparison, providing insights into treatment options. Radiologist
SPEAKER : Dr. Anand Zade
REVIEWER: B. A. Krishna

In association with



Scan & Register





AGENDA

12th July 2025

- 13:30 - 13:35 ➤ **Abstract 28** - Results of a randomized phase III trial of pre-operative chemo-therapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma
SPEAKER : Dr. Asif Shaikh
REVIEWER : Dr. Tejinder Singh
- 13:35 - 13:40 ➤ **Abstract 29** - PANOVA-3: Phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC)
SPEAKER : Dr. Ankit Patel
REVIEWER : Dr. Tejinder Singh
- 13:40 - 14:00 ➤ **Abstract Based Panel Discussion** : Pancreatic Cancer
Moderator : Dr. Vivek Agarwala
PANELISTS : Dr. Jeyhan B. Dhabhar | Dr. Asif Shaikh | Dr. Ankit Patel
Dr. Anand Zade | Dr. Deepak Chhabra | Dr. Prashant Mullerpatan
Dr. Sachin Vani | Dr. Sandeep De | Dr. Sunil Chopade
Dr. Mary Annie Joseph

SESSION 5 COLORECTAL


Chairperson : Dr. Shirish Alurkar | Dr. Jayesh Gori | Dr. Shishir Shetty

- 14:00 - 14:05 ➤ **Abstract 30** - GRANITE Study (LBA13)
This phase 2 trial explores individualized neoantigen-targeting immunotherapy in metastatic microsatellite-stable colorectal cancer (MSS-CRC). Early results show improved progression-free survival (PFS) and long-term circulating tumor DNA (ctDNA) response compared to standard fluoropyrimidine and bevacizumab.
SPEAKER : Dr. Mubarakunnisa Tonse
REVIEWER : Dr. Shirish Alurkar
- 14:05 - 14:10 ➤ **Abstract 31** - CheckMate 8HW (LBA143)
This trial compares nivolumab plus ipilimumab with nivolumab monotherapy in MSI-H/dMMR metastatic CRC, showing promising results for the combination therapy.
SPEAKER : Dr. Arnav Tongaonkar
REVIEWER : Dr. Shirish Alurkar
- 14:10 - 14:15 ➤ **Abstract 32** - BREAKWATER Trial
Phase III study of first-line encorafenib + cetuximab + chemotherapy vs standard of care for BRAF V600E-mutant mCRC, demonstrating potential for improved treatment outcomes.
SPEAKER : Dr. Ravi Jaiswal
REVIEWER : Dr. Shirish Alurkar
- 14:15 - 14:20 ➤ **Abstract 33** - Botensilimab ± Balstilimab
Refractory microsatellite-stable metastatic colorectal cancer without liver metastases treatment shows promise.
SPEAKER : Dr. Madhura Agre
REVIEWER : Dr. Devendra Pal

In association with

Scan & Register






AGENDA

12th July 2025

- 14:20 - 14:25 ➤ **Abstracts 34** - PRODIGE 23 Trial
Total neoadjuvant therapy with modified FOLFIRINOX improved overall survival in locally advanced rectal cancer, with 7-year disease-free survival rate of 67.6% vs 62.5% with standard chemoradiation.
SPEAKER : Dr. Lovin Wilson
REVIEWER: Dr. Devendra Pal
- 14:25 - 14:30 ➤ **Abstracts 35** - Alliance A021502 (ATOMIC) Trial
This study explores the use of atezolizumab combined with standard chemotherapy as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer. Positive results may change the treatment landscape for mismatch repair-deficient/microsatellite instability-high stage III colon cancer.
SPEAKER : Dr. Sowmica Devabhaktuni
REVIEWER: Dr. Devendra Pal
- 14:30 - 14:35 ➤ **Surgical Abstract 36** -Extent of Lymphadenectomy for Surgical Management of Right-Sided Colon Cancer: The Randomized Phase III RELARC Trial
SPEAKER : Dr. Abhijeet Tehre
REVIEWER: Dr. Kamran Khan
- 14:35 - 14:40 ➤ **Surgical Abstract 37** - Long-Term Results of 2-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis for Low Rectal Cancer A Randomized Clinical Trial
SPEAKER : Dr. Jitendra Rohila
REVIEWER: Dr. Kamran Khan
- 14:40 - 14:45 ➤ **Surgical Abstract 38** - Short-term clinical outcomes of open, laparoscopic, and robotic-assisted rectal resections: a multicenter real-world evidence study from Indian collaborative group on rectal resections (ICGRR)
SPEAKER : Dr. Ghanish Panjwani
REVIEWER: Dr. Tanveer Abdul Majeed
- 14:45 - 14:50 ➤ **Surgical Abstract 39** - Transanal vs Laparoscopic Total Mesorectal Excision and 3-Year Disease-Free Survival in Rectal Cancer The TaLaR Randomized Clinical Trial
SPEAKER : Dr. Prashant R Rao
REVIEWER: Dr. Tanveer Abdul Majeed
- 14:50 - 15:10 ➤ Panel Discussion: Colorectal Cancer case based discussion
MODERATOR : Dr. Peush Bajpai
PANELIST: Dr. Mubarakunnisa Tonse | Dr. Shirish Alurkar
Dr. Arnav Tongaonkar | Dr. Ravi Jaiswal | Dr. Madhura Agre
Dr. Devendra Pal | Dr. Lovin Wilson | Dr. Sowmica Devabhaktuni
Dr. Abhijeet Tehre | Dr. Prashant R Rao | Dr. Jitendra Rohila
Dr. Ghanish Panjwani | Dr. Tanveer Abdul Majeed | Dr. Shishir Shetty
- 15:10 - 15:30 ➤ Changing Paradigm in Management of Esophageal Concern - Sponsored by MSD
SPEAKER : Dr. Vaibhav Choudhary
- 15:30 - 15:50 ➤ IO combination is the new paradigm shift in the management of uHCC - Sponsored by AstraZeneca
SPEAKER : Dr. Vineet Talwar





AGENDA

12th July 2025

15:50 - 16:10 ➤ The SCAFIGC trial (NCT05942573) is a phase 2 study investigating the efficacy and safety of serplulimab-based therapy in advanced gastric/gastroesophageal junction (G/GEJ) cancer - (Sponsored by INTAS)
SPEAKER : Dr. Tejinder Singh

16:10 - 16:30 ➤ **TEABREAK**

SESSION 6 MULTIDISCIPLINARY APPROACH

Chair Persons : Dr Sanjay Sharma | Dr. Nagraj Huilgol | Dr. N. Arulvanan

16:30 - 16:50 ➤ **Abstract Based Panel Discussion**
Multi Disciplinary Approach - Colorectal Cancer

MODERATOR : Dr. Jagannath dixit

**PANELIST : Dr. Deepanjali Adulkar | Dr. Sagar Gayakwad | Dr. Pritam Kataria
Dr. Tasneem B | Dr. Avinsh Talele | Dr. Viraj Borgaonkar
Dr. Tanveer AbdulMajeed | Dr. Jayesh Gori**

16:50 - 17:30 ➤ Immune Checkpoint Inhibitors in 1L Gastric Cancer, GE Junction Cancer & Esophageal Adenocarcinomas - BMS Sponsored Session

MODERATOR: Dr. Adwaita Gore

**PANELIST: Dr. Nilesh Lokeshwar | Dr. Suman Mittal | Dr. Vijay Sharnangat
Dr. Jay Mehta**

17:30 - 18:00 ➤ Sponsored Session - Eli Lilly

18:00 - 18:30 ➤ Sponsored Session

18:30 - 18:50 ➤ Sponsored Session - Guardant Health

18:50 - 19:10 ➤ Sponsored Session - SNGENE


19:10 - 19:30 ➤ Sponsored Session - Changing Paradigm in Management of Esophageal Concern - Sponsored by Roche

19:30 onward ➤ **DINNER**

In association with

Scan & Register





AGENDA


13th July 2025

- 07:30 - 09:00 ➤ Breakfast & Registration
Reviewer - Dr. Shirish Alurkar | Dr. Tejinder Singh | Dr. Anil Heroor | Dr. Bharat Parikh
- 08:00 - 08:10 ➤ Poster /Abstract Presentation
DM DNB MS MCh Students
- 08:10 - 08:20 ➤ Poster /Abstract Presentation
DM DNB MS MCh Students
- 08:20 - 08:30 ➤ Poster /Abstract Presentation
DM DNB MS MCh Students
- 08:30 - 08:40 ➤ Poster /Abstract Presentation
DM DNB MS MCh Students
- 08:40 - 08:50 ➤ Poster /Abstract Presentation
DM DNB MS MCh Students
- 08:50 - 09:00 ➤ Poster /Abstract Presentation
DM DNB MS MCh Students

Chairperson : Dr. Sachin Kadam | Dr. Arun Mane

- 09:00 - 09:10 ➤ **Abstract Presentation** - REAL-WORLD Study: Atezolizumab/Bevacizumab in Child-Pugh B HCC
Speaker : Dr. Hemalatha Kalwad
- 09:10 - 09:20 ➤ **Abstract Presentation** - VASC-BIL: Portal Vein and Arterial Reconstruction Outcomes in Locally Advanced Cholangiocarcinoma
Speaker : Dr. Vivek Sukumar
- 09:20 - 09:30 ➤ **Abstract Presentation** - APOLLO Trial: Robotic vs Laparoscopic Low Anterior Resection for Mid/Low Rectal Cancer
Speaker : Dr. Amit Gupta
- 09:30 - 09:40 ➤ **Abstract Presentation** - LACC II Study: Minimally Invasive vs Open Radical Surgery in Early-Stage Gastric Cancer
Speaker : Dr. Viraj Borgaonkar
- 09:40 - 09:50 ➤ **Abstract Presentation** - Neoadjuvant Imatinib in Rectal GIST: Surgical Morbidity and Functional Preservation (NeoRect-GIST Study)
Speaker : Dr. Mohit Relekar
- 09:50 - 10:00 ➤ **Abstract Presentation** - The value and indications for surgery in pancreatic cancer with synchronous liver metastases.
Speaker : Dr. Saneya Pandrowala





AGENDA

13th July 2025

UPPER GI

Chairperson **Dr. Sudhesh Phanse** | **Dr. Avanish Saklani** | **Dr. Raman Deshpande**

- 10:00- 10:20 ➤ **Video – Esophagectomy** **Dr. Srijan Shukla**
Video – Gastrectomy **Dr. Swapnil Patel**
- 10:20- 10:30 ➤ **Sponsored Session**
- 10:30 - 10:55 ➤ Panel Discussion - Right choice of surgery in GE junction tumors
Moderator: Dr. George Karimundackal
Panelist : **Dr. Raman Deshpande** | **Dr. Srijan Shukla** | **Dr. Viraj Borgaonkar**
Dr. Shivam Shingla | **Dr. Amit Gupta** | **Dr. Vikas Gupta**
Dr. Nilesh Choradiya | **Dr. Bhavin Visariya** | **Dr. Swapnil Kapote**
Dr. Sachin Bhojankar | **Dr. Awaita Gore** | **Dr. Shirish Alurkar**

HPB

Chairperson : **Dr. Mahadeo Garale** | **Dr. Shivam Shingla**

- 10:55 - 11:15 ➤ Pembrolizumab in The Management of MUI-H/ D-MMR Advanced -Sponsored Session- MSD
SPEAKER : Dr. Prabhat Bhargava
- 11:15 - 11:30 ➤ Perioperative management of biliary tract cancers
SPEAKER : Dr. Prabhat Bhargava
- 11:30 - 11:50 ➤ Video 1 : Robotic caudate lobe HCC excision
Video 2 : Robotic uncinata process insulinoma excision
SPEAKER : Dr. Mahesh Patel
- 11:50 - 12:00 ➤ **Sponsored Session**

LOWER GI

Chairperson : **Dr. Umesh Borwanka** | **Dr. Amol Gosavi** | **Dr. Hemant Patil**

- 12:00 - 12:15 ➤ MASTERVIDEO
SPEAKER : Dr. Avinash Saklani
- 12:15 - 12:30 ➤ Debate - Rectal Cancer Laproscopy Vs Robotic Surgery
EXPERT : Dr. Avinash Saklani
LAPROSCOPY : Dr. Ajay Punpale
ROBOTIC : Dr. Sandeep Nayak
- 12:30 - 13:00 ➤ **Panel Discussion:** Case based panel discussion - APPENDICEAL CANCERS
MODERATOR : Dr. Muffadil Kazi
PANELIST : **Dr. Swapnil Kapote** | **Dr Yogen Chedda** | **Dr. Amrita Shrivastava**
Dr. Ghanish Panjwani | **Dr. Ashutosh Kharche** | **Dr. Pushkar Ingle**
Dr. Deepak Kumar Dangwal | **Dr. Tejinder singh**
Dr. Advait Sanjay Sonar
- 13:00 onwards ➤ **Lunch**

